Clinical Trials Logo

Myelosuppression Adult clinical trials

View clinical trials related to Myelosuppression Adult.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03793205 Recruiting - Gynecologic Cancer Clinical Trials

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

Start date: January 3, 2019
Phase: Phase 4
Study type: Interventional

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.

NCT ID: NCT03740464 Recruiting - Clinical trials for Epithelial Ovarian Cancer

Long-acting G-CSF for Febrile Neutropenia

Start date: November 10, 2018
Phase: Phase 3
Study type: Interventional

This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer. Patients are randomized into study group and control group. In study group, patients accept long-acting G-CSF 48 hours from the chemotherapy. While the control group accept regular treatment rather than long-acting G-CSF. The primary end is the incidence of FN in every course of chemotherapy. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.